<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pituitary</journal-id>
      <journal-id journal-id-type="iso-abbrev">Pituitary</journal-id>
      <journal-title-group>
        <journal-title>Pituitary</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1386-341X</issn>
      <issn pub-type="epub">1573-7403</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>Boston</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24293348</article-id>
      <article-id pub-id-type="pmc">3906541</article-id>
      <article-id pub-id-type="publisher-id">538</article-id>
      <article-id pub-id-type="doi">10.1007/s11102-013-0538-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Aggressive tumors and difficult choices in acromegaly</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Carrasco</surname>
            <given-names>Carmen A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gadelha</surname>
            <given-names>M&#xF4;nica</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manavela</surname>
            <given-names>Marcos</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Bruno</surname>
            <given-names>Oscar D.</given-names>
          </name>
          <address>
            <phone>+54-11-43280268</phone>
            <fax>+54-11-48050631</fax>
            <email>bodomingo@intramed.net</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <aff id="Aff1"><label/>Departamento de Endocrinolog&#xED;a, Facultad de Medicina, Pontificia Universidad Cat&#xF3;lica de Chile, Santiago, Chile </aff>
        <aff id="Aff2"><label/>Endocrinology Section, Hospital Universit&#xE1;rio Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil </aff>
        <aff id="Aff3"><label/>Division of Endocrinology, Hospital de Cl&#xED;nicas, University of Buenos Aires, Av. C&#xF3;rdoba 2351, 1120 Buenos Aires, Argentina </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>12</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2014</year>
      </pub-date>
      <volume>17</volume>
      <issue>Suppl 1</issue>
      <fpage>24</fpage>
      <lpage>29</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p>The current article looks at some of the factors associated with pituitary adenomas displaying unusually aggressive biological and clinical behaviour in patients with acromegaly.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>This was a retrospective, narrative review of previously published evidence chosen at the authors&#x2019; discretion and presented from the perspective of a Latin American case study.</p>
        </sec>
        <sec>
          <title>Findings and Conclusions</title>
          <p>Although most pituitary tumors in acromegalic patients are benign and non-aggressive many can behave more aggressively, compromising local surrounding structures. These lesions tend to respond poorly to somatostatin analogs, have a higher risk of recurrence after surgery and, thus, a worse prognosis. Patients with more aggressive tumors constitute a particular challenge, as they often require several therapeutic approaches and may be difficult to manage, especially when options are restricted due to limited resources.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Acromegaly</kwd>
        <kwd>GH</kwd>
        <kwd>IGF-1</kwd>
        <kwd>Aggressive tumors</kwd>
        <kwd>Somatostatin analogs</kwd>
        <kwd>Dopamine agonists</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media New York 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Most pituitary tumors in acromegalic patients are benign and respond well to multimodal therapy [<xref ref-type="bibr" rid="CR1">1</xref>]. Nevertheless, many pituitary adenomas can behave in a more aggressive manner, with more rapid growth, local invasion into the surrounding structures, greater risk of recurrence after surgery and worse prognosis [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. Patients with invasive and more aggressive GH-secreting tumors often require several therapeutic approaches and may be difficult to manage [<xref ref-type="bibr" rid="CR1">1</xref>], especially when options are restricted due to limited resources. The current article presents a case report of a somatotropic tumor with aggressive behavior and discusses some of the treatment challenges and difficult choices that this can impose in Latin America.</p>
    </sec>
    <sec id="Sec2">
      <title>What defines an aggressive tumor in acromegaly?</title>
      <p>Tumor aggressiveness can be based on clinical, radiological and pathological features. However, there are no well-defined absolute criteria for defining an aggressive pituitary tumor. The 2004 World Health Organization classification of pituitary tumors defined three primary types&#x2014;&#x201C;typical pituitary adenoma&#x201D;, &#x201C;atypical pituitary adenoma&#x201D; and &#x201C;pituitary carcinoma&#x201D; [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The rather poorly defined &#x201C;atypical&#x201D; designation was an attempt to identify those adenomas that are likely to display more aggressive behavior with increased proliferative activity. The specific &#x201C;atypical&#x201D; characteristics that were identified included invasion into the cavernous sinuses, an elevated proliferation index [Ki-67 labeling index (LI) &gt;3&#xA0;%] and nuclear reactivity for p. 53 [<xref ref-type="bibr" rid="CR4">4</xref>]. However, the true value of these and other biomarkers in predicting aggressive and progressive tumor behavior in clinical practice remains uncertain [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Many studies have found strong associations between Ki-67 labeling and tumor invasiveness, tumor size and recurrence, but there is inconsistency in the data, which may, at least in part, relate to the different criteria and measures used to define factors such as invasiveness [<xref ref-type="bibr" rid="CR8">8</xref>]. Histologic subtyping may be the best predictor of aggressive behavior once surgical biopsies have been taken, particularly with regards to the presence of sparse granulation in somatotroph (i.e., growth hormone-secreting) adenomas, although subtyping into sparse versus dense granulation does not absolutely predict aggressiveness and many biopsies may show intermediate characteristics [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>Radiological assessment of gross tumor invasiveness may be more clinically useful, especially as it can also provide an initial assessment of aggressive behavior obviating the need for intraoperative biopsies. At the time of acromegaly diagnosis, macroadenomas (tumors &gt;10&#xA0;mm in diameter) represent approximately 80&#xA0;% of GH secreting adenomas [<xref ref-type="bibr" rid="CR12">12</xref>&#x2013;<xref ref-type="bibr" rid="CR14">14</xref>]. Although definitions of invasiveness vary, approximately 25&#x2013;50&#xA0;% of these macroadenomas can be defined as grossly invasive according to the most widely used radiological or surgical criteria (which are based on the degree of suprasellar extension or lateral extension into the cavernous sinus) [<xref ref-type="bibr" rid="CR11">11</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>&#x2013;<xref ref-type="bibr" rid="CR21">21</xref>]. Around 50&#xA0;% or more of tumors might be considered as invasive if microscopic invasion of the local dura is employed as the criterion [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>].</p>
      <p>Several other clinically-relevant factors such as young age at diagnosis, large tumor size, and high GH secretion have also been identified as predictors of aggressive behavior [<xref ref-type="bibr" rid="CR1">1</xref>]. Although pediatric cases of acromegaly are uncommon, these cases may present with more aggressive and larger tumors and, as such, may require more intensive management [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p>
    </sec>
    <sec id="Sec3">
      <title>Resistance to therapy</title>
      <p>As expected, the surgical cure rate is reduced for invasive tumors and many may be considered inoperable, thus necessitating other options, such as pharmacological intervention. In general, the surgical long-term remission rate for microadenomas is approximately 80&#xA0;%, but this decreases to less than 50&#xA0;% for macroadenomas and only 25&#x2013;30&#xA0;% for macroadenomas classified as grossly invasive [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Extrasellar tumor growth, mixed tumors (GH- and prolactin-secreting), dural invasion, tumor size, cavernous sinus invasion, Knosp grade, and pre-operative GH and IGF-1 levels have all been shown to be predictors of poor surgical outcome [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Persistent disease after surgery might require repeat surgery, which is indicated if there is residual tumor that is surgically accessible with a chance for surgical cure (or with persistent mass effects on the optic chiasm) [<xref ref-type="bibr" rid="CR28">28</xref>], although pharmacological therapy is indicated if this is not the case.</p>
      <p>Resistance to pharmacological therapy may be another manifestation of aggressive disease. In the case of somatostatin analogs (SSAs) many factors have been identified that predict a better response and some of these may be worth considering before commencing therapy [<xref ref-type="bibr" rid="CR29">29</xref>]. For instance, older age and lower circulating GH levels at diagnosis have all been associated with better SSA response, and a positive acute SSA test (showing 75&#xA0;% GH reduction) may also help to predict longer-term responsiveness [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Other accessible measures, such as a hyperintense lesion on T2-weighted on MRI can predict a poor response, as can the presence of sparse GH tumor granulation histology [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Various immunohistochemical assays for biochemical markers, such as Ki-67 LI (which is lower in responders), somatostatin receptor subtype 2 (SSTR2) expression, SSTR2/SSTR5 ratio and especially wild-type aryl hydrocarbon receptor-interacting protein (AIP) expression (which are all increased in responders) may also be useful for predicting response if biopsies are available. Recent data suggest that AIP can predict response to SSA therapy independently of SSTR2 expression, whereas the combination of both high AIP and high SSRT2 expression appears to be a particularly good predictor [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. Recent evidence also suggests that SSAs increase the expression of AIP and that it might play an important role in their mechanism of action [<xref ref-type="bibr" rid="CR33">33</xref>]. However, these markers are not well validated in clinical practice and may not be widely available due to cost restrictions [<xref ref-type="bibr" rid="CR29">29</xref>]. Nevertheless, if available, such factors may help to inform clinicians when making decisions about costly therapies.</p>
      <p>The use of surgery to reduce tumor mass may help to improve the response to SSAs treatment in those resistant to primary SSAs therapy [<xref ref-type="bibr" rid="CR34">34</xref>]. However, in those patients in whom all surgical and pharmacological approaches have failed to control the disease, radiotherapy is the only viable option [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. That said, novel pharmacological interventions are being investigated for the treatment of particularly aggressive pituitary tumors, most notably the orally administered alkylating agent temozolomide [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. However, experience with these agents specifically in patients with aggressive GH-secreting adenomas is extremely limited at present.</p>
    </sec>
    <sec id="Sec4">
      <title>Case study: difficult choices in a patient with invasive macroadenoma</title>
      <p>
        <list list-type="bullet">
          <list-item>
            <p>A 31-year-old man was referred by his cardiologist because of acral growth and deformity of facial features</p>
          </list-item>
          <list-item>
            <p>He was noted to have hypertension and impaired glucose tolerance 3-years earlier</p>
          </list-item>
          <list-item>
            <p>He also complained of fatigue and headache, arthralgia, carpal tunnel syndrome and erectile dysfunction</p>
          </list-item>
          <list-item>
            <p>Past medical history and familial history were unremarkable</p>
          </list-item>
        </list>
      </p>
      <p>Physical examination (initial evaluation) 
<list list-type="bullet"><list-item><p>Clinical findings were hypertension, acral enlargement, prognathism, supracilliary arch prominence, macroglossia, gynecomastia and thickened skin</p></list-item><list-item><p>No visual field defects</p></list-item></list>Hormonal evaluation 
<list list-type="bullet"><list-item><p>GH nadir during OGTT&#xA0;=&#xA0;17.3&#xA0;&#x3BC;g/L [2-h glucose&#xA0;=&#xA0;8.8&#xA0;mmol/L (158&#xA0;mg/dL)]</p></list-item><list-item><p>IGF-1: 1,162&#xA0;&#x3BC;g/L (normal 117&#x2013;329&#xA0;&#x3BC;g/L)</p></list-item><list-item><p>T4: 103&#xA0;nmol/L [8.0&#xA0;&#x3BC;g/dL (normal 4.6&#x2013;12&#xA0;&#x3BC;g/dL)]</p></list-item><list-item><p>TSH: 2.1&#xA0;mIU/L (normal 0.3&#x2013;4.1&#xA0;mIU/L)</p></list-item><list-item><p>Total testosterone: 5.5&#xA0;nmol/L [159&#xA0;ng/dL (normal 280&#x2013;1,100&#xA0;ng/dL)]</p></list-item><list-item><p>Prolactin: 11.6&#xA0;nmol/L [267&#xA0;&#x3BC;g/L (normal 2&#x2013;20&#xA0;&#x3BC;g/L)]</p></list-item><list-item><p>Basal cortisol/post Synacthen: 196/737&#xA0;nmol/L (7/27&#xA0;&#x3BC;g/dL)</p></list-item></list>Pre-treatment MRI 
<list list-type="bullet"><list-item><p>Post-contrast coronal T1 MRI showed 18&#xA0;&#xD7;&#xA0;13&#xA0;mm macroadenoma in the right and inferior portion of the pituitary, with invasion of sphenoidal sinus and erosion of sphenoid and clivus. Tumor had hypointense signal and normal hypophysis showed homogeneous enhancement at left (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a, b) 
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Case study: post-contrast, T1-weighted MRI scans of pituitary tumor at diagnosis (<bold>a</bold>), before surgery (<bold>b</bold>) and three months after surgery (<bold>c</bold>) (coronal<italic> left</italic>, sagittal<italic> right</italic>)</p></caption><graphic xlink:href="11102_2013_538_Fig1_HTML" id="MO1"/></fig></p></list-item></list>Diagnosis 
<list list-type="bullet"><list-item><p>Acromegaly (with co-secretion of prolactin)</p></list-item><list-item><p>Invasive macroadenoma without mass effect</p></list-item><list-item><p>Hypogonadotrophic hypogonadism</p></list-item></list>Initial treatment 
<list list-type="bullet"><list-item><p>Transsphenoidal surgery was performed (June 2009) in an attempt to improve the response to cabergoline or radiation therapy (SSAs were not included in medical insurance in Chile at the time of diagnosis)</p></list-item><list-item><p>Histopathology evaluation showed positive staining for GH and prolactin, perinuclear cytokeratin staining (densely granulated) and Ki-67 LI 4.7&#xA0;%</p></list-item><list-item><p>Predictors of poor surgical outcome were extrasellar growth (clivus invasion) and mixed tumor</p></list-item></list>3-Months follow-up 
<list list-type="bullet"><list-item><p>IGF-1 1193&#xA0;&#x3BC;g/L (normal 115&#x2013;307&#xA0;&#x3BC;g/L)</p></list-item><list-item><p>Random GH 10.2&#xA0;&#x3BC;g/L</p></list-item><list-item><p>GH nadir 8.6&#xA0;&#x3BC;g/L</p></list-item><list-item><p>MRI: 13&#xA0;mm clivus residual tumor (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>c)</p></list-item></list>Subsequent treatment and course 
<list list-type="bullet"><list-item><p>Cabergoline (3&#x2013;5&#xA0;mg weekly) was initiated in September 2009 without obtaining normalization of IGF-1</p></list-item><list-item><p>Radiation therapy was performed in June 2010 without normalization of IGF-1</p></list-item><list-item><p>In July 2010, SSAs were initiated as add-on therapy to cabergoline</p></list-item><list-item><p>Biochemical cure was not achieved despite maximal doses of SSA</p></list-item><list-item><p>Currently, random GH is 1.58&#xA0;&#x3BC;g/L (ECLIA), IGF-1 650&#xA0;&#x3BC;g/L, hypertension and impaired glucose tolerance are under control and no symptoms of obstructive sleep apnea are present. The patient complains of fatigue and joint pain</p></list-item></list></p>
    </sec>
    <sec id="Sec5">
      <title>Case discussion</title>
      <p>This case provides an example of the difficult choices that have to be made in situations where access to some therapies is limited by local constraints, such as lack of reimbursement for specific drugs. The recommended first-line therapy in this patient was an SSA (possibly in combination with a dopamine agonist due to prolactin co-secretion). Due to the invasiveness of the tumor, the patient had a low chance of surgical cure. However, due to lack of access to SSAs at the time of diagnosis, a treatment plan had to be made based on the available local resources&#x2014;in this case, surgery followed by cabergoline. Although the patient did not achieve biochemical remission even after SSAs became available, the patient has remained relatively stable. This introduces another dilemma regarding decisions to continue a pharmacological therapy or withdraw it and put the patient at risk of deterioration. Pressure to withdraw costly long-term pharmacological therapy may be considerable in areas with limited resources. Region-specific cost analyses would be useful to justify long-term pharmacological therapy in such situations. A further dilemma is whether to accept stable, but suboptimal, disease control or to intensify therapy further with additional cost. Guidelines recommend that patients should remain on the same dose for at least 3&#xA0;months (assuming the patient tolerates the medication) to properly assess adequacy of treatment and the need for dose titration or switching to the GH receptor antagonist pegvisomant [<xref ref-type="bibr" rid="CR39">39</xref>]. In the current case, intensification of pharmacological therapy beyond SSAs using the GH receptor antagonist pegvisomant was not possible, as it was not included in Chilean medical insurance programs.</p>
    </sec>
    <sec id="Sec6" sec-type="conclusion">
      <title>Conclusions</title>
      <p>Choosing the correct individually tailored therapeutic option in a patient with acromegaly in line with current guidelines is a challenge, even when access to all available surgical, pharmacological and radiotherapeutical resources is available. This is particularly true in patients with more aggressive disease. Failure to achieve hormonal control in acromegaly puts patients at risk for early mortality, suggesting the need for aggressive efforts to normalize hormone levels [<xref ref-type="bibr" rid="CR40">40</xref>]. In patients with aggressive, invasive tumors, access to all available options thus becomes paramount. The prognosis of surgery will depend on the characteristics of the tumor, but importantly, also on the experience of the neurosurgeon when it comes to treat patients with more invasive tumors [<xref ref-type="bibr" rid="CR26">26</xref>].</p>
      <p>The SSAs have a role as primary pharmacological therapy and as adjuvant therapy after surgery or radiation in patients with aggressive tumors. Newer drugs such as GH receptor antagonists can be effective in normalization of IGF-I in patients who do not respond to SSAs, but with a very high cost and access to these drugs may not be possible in many areas of Latin America [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Combination therapy with SSAs and a GH receptor antagonist may be a safe and effective option that can help to lower doses and reduce the costs of pharmacological treatment [<xref ref-type="bibr" rid="CR43">43</xref>&#x2013;<xref ref-type="bibr" rid="CR45">45</xref>]. Lower cost, but less effective, medications, such as dopamine agonists maybe the only pharmacological options available in areas with restricted resources. Fortunately, SSAs are becoming more widely available across Latin American countries and the use of pharmacological therapy has increased markedly over the last 10&#xA0;years. Further development of the use of biomarkers to predict aggressive and invasive tumor behavior, as well as response to pharmacological therapy may help clinicians to make more informed treatment choices early and make more effective use of available resources.</p>
      <p>In summary, in countries with less access to experienced pituitary surgeons and with limited access to all available pharmacological therapies, management of aggressive GH tumors is particularly complex and physicians may need to make difficult choices based on available resources. Methods to improve judicious treatment selection, such as the use of histological evaluation or development of new reliable and accessible biomarkers predicting response to therapy, may provide a means to optimize resource utilization.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>The Latin American Knowledge Network Initiative, including meetings and preparation of this supplement, was organized and funded by Ipsen. Medical writing support was provided by Patrick Covernton on behalf of Arsenal-CDM Paris and funded by Ipsen. The authors were fully responsible for the concept and all content, were involved at all stages of manuscript development, and provided approval of the final version for submission.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Besser</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Burman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Predictors and rates of treatment-resistant tumor growth in acromegaly</article-title>
          <source>Eur J Endocrinol</source>
          <year>2005</year>
          <volume>153</volume>
          <issue>2</issue>
          <fpage>187</fpage>
          <lpage>193</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.01968</pub-id>
          <pub-id pub-id-type="pmid">16061822</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buchfelder</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Management of aggressive pituitary adenomas: current treatment strategies</article-title>
          <source>Pituitary</source>
          <year>2009</year>
          <volume>12</volume>
          <issue>3</issue>
          <fpage>256</fpage>
          <lpage>260</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-008-0153-z</pub-id>
          <pub-id pub-id-type="pmid">19003540</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grasso</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Therapy of aggressive pituitary tumors</article-title>
          <source>Expert Opin Pharmacother</source>
          <year>2011</year>
          <volume>12</volume>
          <issue>10</issue>
          <fpage>1561</fpage>
          <lpage>1570</lpage>
          <pub-id pub-id-type="doi">10.1517/14656566.2011.568478</pub-id>
          <pub-id pub-id-type="pmid">21434849</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Shraim</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Asa</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>The 2004 World Health Organization classification of pituitary tumors: what is new?</article-title>
          <source>Acta Neuropathol</source>
          <year>2006</year>
          <volume>111</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1007/s00401-005-1093-6</pub-id>
          <pub-id pub-id-type="pmid">16328527</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kontogeorgos</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Predictive markers of pituitary adenoma behavior</article-title>
          <source>Neuroendocrinology</source>
          <year>2006</year>
          <volume>83</volume>
          <issue>3&#x2013;4</issue>
          <fpage>179</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="doi">10.1159/000095526</pub-id>
          <pub-id pub-id-type="pmid">17047381</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gejman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Swearingen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hedley-Whyte</surname>
              <given-names>ET</given-names>
            </name>
          </person-group>
          <article-title>Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas</article-title>
          <source>Hum Pathol</source>
          <year>2008</year>
          <volume>39</volume>
          <issue>5</issue>
          <fpage>758</fpage>
          <lpage>766</lpage>
          <pub-id pub-id-type="doi">10.1016/j.humpath.2007.10.004</pub-id>
          <pub-id pub-id-type="pmid">18439942</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mete</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ezzat</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Asa</surname>
              <given-names>SL</given-names>
            </name>
          </person-group>
          <article-title>Biomarkers of aggressive pituitary adenomas</article-title>
          <source>J Mol Endocrinol</source>
          <year>2012</year>
          <volume>49</volume>
          <issue>2</issue>
          <fpage>R69</fpage>
          <lpage>R78</lpage>
          <pub-id pub-id-type="doi">10.1530/JME-12-0113</pub-id>
          <pub-id pub-id-type="pmid">22822048</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salehi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Agur</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Cusimano</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Ki-67 in pituitary neoplasms: a review&#x2014;part I</article-title>
          <source>Neurosurgery</source>
          <year>2009</year>
          <volume>65</volume>
          <issue>3</issue>
          <fpage>429</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.1227/01.NEU.0000349930.66434.82</pub-id>
          <pub-id pub-id-type="pmid">19687686</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Obari</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ohyama</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kudo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>ZR</given-names>
            </name>
            <name>
              <surname>Yoneda</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rayhan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mustafizur Rahman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form</article-title>
          <source>Endocr Pathol</source>
          <year>2008</year>
          <volume>19</volume>
          <issue>2</issue>
          <fpage>82</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1007/s12022-008-9029-z</pub-id>
          <pub-id pub-id-type="pmid">18629656</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kiseljak-Vassiliades</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Shafi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kerr</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Phang</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Kleinschmidt-DeMasters</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Wierman</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Clinical implications of growth hormone-secreting tumor subtypes</article-title>
          <source>Endocrine</source>
          <year>2012</year>
          <volume>42</volume>
          <issue>1</issue>
          <fpage>18</fpage>
          <lpage>28</lpage>
          <pub-id pub-id-type="doi">10.1007/s12020-012-9660-9</pub-id>
          <pub-id pub-id-type="pmid">22434413</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Larkin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Karavitaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cudlip</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wass</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ansorge</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas</article-title>
          <source>Eur J Endocrinol</source>
          <year>2013</year>
          <volume>168</volume>
          <issue>4</issue>
          <fpage>491</fpage>
          <lpage>499</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-12-0864</pub-id>
          <pub-id pub-id-type="pmid">23288882</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Beauregard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Truong</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Hardy</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Serri</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2003</year>
          <volume>58</volume>
          <issue>1</issue>
          <fpage>86</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2265.2003.01679.x</pub-id>
          <pub-id pub-id-type="pmid">12519417</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Minniti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jaffrain-Rea</surname>
              <given-names>M-L</given-names>
            </name>
            <name>
              <surname>Esposito</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tamburrano</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cantore</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature</article-title>
          <source>Endocr Relat Cancer</source>
          <year>2003</year>
          <volume>10</volume>
          <issue>4</issue>
          <fpage>611</fpage>
          <lpage>619</lpage>
          <pub-id pub-id-type="doi">10.1677/erc.0.0100611</pub-id>
          <pub-id pub-id-type="pmid">14713271</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mestron</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Astorga</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Benito</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Catala</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gaztambide</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gomez</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Halperin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lucas-Morante</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Moreno</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Obiols</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>de Pablos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Paramo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pico</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Varela</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Vazquez</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Zamora</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Albareda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gilabert</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)</article-title>
          <source>Eur J Endocrinol</source>
          <year>2004</year>
          <volume>151</volume>
          <issue>4</issue>
          <fpage>439</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.0.1510439</pub-id>
          <pub-id pub-id-type="pmid">15476442</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Randall</surname>
              <given-names>RV</given-names>
            </name>
          </person-group>
          <article-title>Pathology of invasive pituitary tumors with special reference to functional classification</article-title>
          <source>J Neurosurg</source>
          <year>1986</year>
          <volume>65</volume>
          <issue>6</issue>
          <fpage>733</fpage>
          <lpage>744</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1986.65.6.0733</pub-id>
          <pub-id pub-id-type="pmid">3095506</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Knosp</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kitz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matula</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings</article-title>
          <source>Neurosurgery</source>
          <year>1993</year>
          <volume>33</volume>
          <issue>4</issue>
          <fpage>610</fpage>
          <lpage>617</lpage>
          <pub-id pub-id-type="doi">10.1227/00006123-199310000-00008</pub-id>
          <pub-id pub-id-type="pmid">8232800</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thapar</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Stefaneanu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Killinger</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Lioyd</surname>
              <given-names>RV</given-names>
            </name>
            <name>
              <surname>Smyth</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Barr</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thorner</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Gaylinn</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behavior</article-title>
          <source>Am J Pathol</source>
          <year>1997</year>
          <volume>151</volume>
          <issue>3</issue>
          <fpage>769</fpage>
          <lpage>784</lpage>
          <pub-id pub-id-type="pmid">9284826</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Esposito</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Santoro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Minniti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Salvati</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Innocenzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lanzetta</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cantore</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumors: outcome analysis in a series of 125 patients</article-title>
          <source>Neurol Sci</source>
          <year>2004</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>251</fpage>
          <lpage>256</lpage>
          <pub-id pub-id-type="doi">10.1007/s10072-004-0351-z</pub-id>
          <pub-id pub-id-type="pmid">15624082</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saeger</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>L&#xFC;decke</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Buchfelder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fahlbusch</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Quabbe</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Petersenn</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Pathohistological classification of pituitary tumors: 10&#xA0;years of experience with the German Pituitary Tumor Registry</article-title>
          <source>Eur J Endocrinol</source>
          <year>2007</year>
          <volume>156</volume>
          <issue>2</issue>
          <fpage>203</fpage>
          <lpage>216</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.02326</pub-id>
          <pub-id pub-id-type="pmid">17287410</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kim</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Jang</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>OL</given-names>
            </name>
          </person-group>
          <article-title>Surgical results of growth hormone-secreting pituitary adenoma</article-title>
          <source>J Korean Neurosurg Soc</source>
          <year>2009</year>
          <volume>45</volume>
          <issue>5</issue>
          <fpage>271</fpage>
          <lpage>274</lpage>
          <pub-id pub-id-type="doi">10.3340/jkns.2009.45.5.271</pub-id>
          <pub-id pub-id-type="pmid">19516943</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dusek</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kastelan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Melada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baretic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Skoric Polovina</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Perkovic</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Giljevic</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Jelcic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Paladino</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aganovic</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Korsic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience</article-title>
          <source>J Endocrinol Invest</source>
          <year>2011</year>
          <volume>34</volume>
          <issue>11</issue>
          <fpage>e382</fpage>
          <lpage>e385</lpage>
          <pub-id pub-id-type="pmid">21750393</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selman</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Carpenter</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>The occurrence of dural invasion in pituitary adenomas</article-title>
          <source>J Neurosurg</source>
          <year>1986</year>
          <volume>64</volume>
          <issue>3</issue>
          <fpage>402</fpage>
          <lpage>407</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1986.64.3.0402</pub-id>
          <pub-id pub-id-type="pmid">3950720</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meij</surname>
              <given-names>BP</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Ellegala</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Alden</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery</article-title>
          <source>J Neurosurg</source>
          <year>2002</year>
          <volume>96</volume>
          <issue>2</issue>
          <fpage>195</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.2002.96.2.0195</pub-id>
          <pub-id pub-id-type="pmid">11838791</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dyer</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Civit</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Visot</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Delalande</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Derome</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Transsphenoidal surgery for pituitary adenomas in children [with discussion]</article-title>
          <source>Neurosurgery</source>
          <year>1994</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>207</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="doi">10.1227/00006123-199402000-00001</pub-id>
          <pub-id pub-id-type="pmid">8177379</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Tara</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>L&#xFC;decke</surname>
              <given-names>DK</given-names>
            </name>
          </person-group>
          <article-title>Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery</article-title>
          <source>Neurosurgery</source>
          <year>1999</year>
          <volume>45</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>10</lpage>
          <pub-id pub-id-type="doi">10.1097/00006123-199907000-00001</pub-id>
          <pub-id pub-id-type="pmid">10414559</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreutzer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Lopes</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <issue>9</issue>
          <fpage>4072</fpage>
          <lpage>4077</lpage>
          <pub-id pub-id-type="pmid">11549628</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jane</surname>
              <given-names>JA</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Starke</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Elzoghby</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Reames</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Payne</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Thorner</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Marshall</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>ER</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
          </person-group>
          <article-title>Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2011</year>
          <volume>96</volume>
          <issue>9</issue>
          <fpage>2732</fpage>
          <lpage>2740</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2011-0554</pub-id>
          <pub-id pub-id-type="pmid">21715544</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Espinosa de los Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Sosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Guinto</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Surgical reintervention in acromegaly: is it still worth trying?</article-title>
          <source>Endocr Pract</source>
          <year>2009</year>
          <volume>15</volume>
          <issue>5</issue>
          <fpage>431</fpage>
          <lpage>437</lpage>
          <pub-id pub-id-type="doi">10.4158/EP09066.ORR</pub-id>
          <pub-id pub-id-type="pmid">19491070</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Kasuki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Korbonits</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Novel pathway for somatostatin analogs in patients with acromegaly</article-title>
          <source>Trends Endocrinol Metab</source>
          <year>2013</year>
          <volume>25</volume>
          <issue>5</issue>
          <fpage>238</fpage>
          <lpage>248</lpage>
          <pub-id pub-id-type="doi">10.1016/j.tem.2012.11.007</pub-id>
          <pub-id pub-id-type="pmid">23270713</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Resistance to somatostatin analogs in acromegaly</article-title>
          <source>Endocr Rev</source>
          <year>2011</year>
          <volume>32</volume>
          <issue>2</issue>
          <fpage>247</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="doi">10.1210/er.2010-0002</pub-id>
          <pub-id pub-id-type="pmid">21123741</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasuki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Colli</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>de Castro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression</article-title>
          <source>Arq Bras Endocrinol Metabol</source>
          <year>2012</year>
          <volume>56</volume>
          <issue>8</issue>
          <fpage>501</fpage>
          <lpage>506</lpage>
          <pub-id pub-id-type="doi">10.1590/S0004-27302012000800007</pub-id>
          <pub-id pub-id-type="pmid">23295289</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kasuki</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Vieira Neto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wildemberg</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Colli</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>de Castro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Takiya</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression</article-title>
          <source>Endocr Relat Cancer</source>
          <year>2012</year>
          <volume>19</volume>
          <issue>3</issue>
          <fpage>L25</fpage>
          <lpage>L29</lpage>
          <pub-id pub-id-type="doi">10.1530/ERC-12-0020</pub-id>
          <pub-id pub-id-type="pmid">22420004</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chahal</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Trivellin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Leontiou</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Alband</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fowkes</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Tahir</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Igreja</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Chapple</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Jordan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lupp</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schulz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ansorge</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Karavitaki</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Carlsen</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wass</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Korbonits</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2012</year>
          <volume>97</volume>
          <issue>8</issue>
          <fpage>E1411</fpage>
          <lpage>E1420</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2012-1111</pub-id>
          <pub-id pub-id-type="pmid">22659247</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jallad</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Musolino</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Kodaira</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cescato</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2007</year>
          <volume>67</volume>
          <issue>2</issue>
          <fpage>310</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2265.2007.02885.x</pub-id>
          <pub-id pub-id-type="pmid">17555503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jallad</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Musolino</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Salgado</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Treatment of acromegaly: is there still a place for radiotherapy?</article-title>
          <source>Pituitary</source>
          <year>2007</year>
          <volume>10</volume>
          <issue>1</issue>
          <fpage>53</fpage>
          <lpage>59</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-007-0002-5</pub-id>
          <pub-id pub-id-type="pmid">17318438</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gonz&#xE1;lez</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Vargas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Espinosa-de-los-Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sosa</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of radiotherapy in acromegaly</article-title>
          <source>Arch Med Res</source>
          <year>2011</year>
          <volume>42</volume>
          <issue>1</issue>
          <fpage>48</fpage>
          <lpage>52</lpage>
          <pub-id pub-id-type="doi">10.1016/j.arcmed.2011.01.004</pub-id>
          <pub-id pub-id-type="pmid">21376263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Syro</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Ortiz</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Lloyd</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Uribe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Cusimano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Horvath</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Treatment of pituitary neoplasms with temozolomide: a review</article-title>
          <source>Cancer</source>
          <year>2011</year>
          <volume>117</volume>
          <issue>3</issue>
          <fpage>454</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.25413</pub-id>
          <pub-id pub-id-type="pmid">20845485</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortiz</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Syro</surname>
              <given-names>LV</given-names>
            </name>
            <name>
              <surname>Scheithauer</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Rotondo</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Uribe</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fadul</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Horvath</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Temozolomide in aggressive pituitary adenomas and carcinomas</article-title>
          <source>Clinics (Sao Paulo)</source>
          <year>2012</year>
          <volume>67</volume>
          <issue>Suppl 1</issue>
          <fpage>119</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="doi">10.6061/clinics/2012(Sup01)20</pub-id>
          <pub-id pub-id-type="pmid">22584716</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Melmed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Molitch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Grossman</surname>
              <given-names>AB</given-names>
            </name>
            <name>
              <surname>Kleinberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Clemmons</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Chanson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Laws</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schlechte</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vance</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Giustina</surname>
              <given-names>A</given-names>
            </name>
            <collab>Acromegaly Consensus Group</collab>
          </person-group>
          <article-title>Guidelines for acromegaly management: an update</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2009</year>
          <volume>94</volume>
          <issue>5</issue>
          <fpage>1509</fpage>
          <lpage>1517</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2008-2421</pub-id>
          <pub-id pub-id-type="pmid">19208732</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sughrue</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Aghi</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Blevins</surname>
              <given-names>LS</given-names>
            </name>
          </person-group>
          <article-title>Excess mortality for patients with residual disease following resection of pituitary adenomas</article-title>
          <source>Pituitary</source>
          <year>2011</year>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>276</fpage>
          <lpage>283</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-011-0308-1</pub-id>
          <pub-id pub-id-type="pmid">21476061</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Colao</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pivonello</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Auriemma</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>De Martino</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Bidlingmaier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Briganti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tortora</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Burman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kourides</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Strasburger</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance</article-title>
          <source>Eur J Endocrinol</source>
          <year>2006</year>
          <volume>154</volume>
          <issue>3</issue>
          <fpage>467</fpage>
          <lpage>477</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.1.02112</pub-id>
          <pub-id pub-id-type="pmid">16498061</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bronstein</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>OD</given-names>
            </name>
            <name>
              <surname>Cob</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Espinosa-de-los-Monteros</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Gadelha</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Garavito</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Guitelman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mangupli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mercado</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Portocarrero</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sheppard</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Management of acromegaly in Latin America: expert panel recommendations</article-title>
          <source>Pituitary</source>
          <year>2010</year>
          <volume>13</volume>
          <issue>2</issue>
          <fpage>168</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1007/s11102-009-0206-y</pub-id>
          <pub-id pub-id-type="pmid">19882249</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>J&#xF8;rgensen</surname>
              <given-names>JO</given-names>
            </name>
            <name>
              <surname>Feldt-Rasmussen</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Frystyk</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Kristensen</surname>
              <given-names>L&#xD8;</given-names>
            </name>
            <name>
              <surname>Hagen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>&#xD8;rskov</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2005</year>
          <volume>90</volume>
          <issue>10</issue>
          <fpage>5627</fpage>
          <lpage>5631</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2005-0531</pub-id>
          <pub-id pub-id-type="pmid">16046586</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feenstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>de Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>ten Have</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>van den Beld</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>365</volume>
          <issue>9471</issue>
          <fpage>1644</fpage>
          <lpage>1646</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(05)63011-5</pub-id>
          <pub-id pub-id-type="pmid">15885297</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neggers</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>de Herder</surname>
              <given-names>WW</given-names>
            </name>
            <name>
              <surname>Janssen</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Feelders</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>van der Lely</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
          <article-title>Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5&#xA0;years (median 2.2&#xA0;years) of follow-up in 86 patients</article-title>
          <source>Eur J Endocrinol</source>
          <year>2009</year>
          <volume>160</volume>
          <issue>4</issue>
          <fpage>529</fpage>
          <lpage>533</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-08-0843</pub-id>
          <pub-id pub-id-type="pmid">19141604</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
